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ABSTRACT 
Objective: To optimize the dosage regimen of fixed-dose combination (FDC) of ceftriaxone/sulbactam (2/1 w/w) using in vitro system, 
pharmacokinetic/pharmacodynamic (PK/PD) modeling and Monte-Carlo simulations (MCS).  
Methods: One compartment in vitro system was used for identification of PK/PD driver that best correlates with therapeutic potential of FDC 
against ESBL positive E. coli infection. Using in vitro approach, the best exposure from dose escalation study was fractionated twice-a-day (BID) and 
thrice-a-day (TID) to determine a best dosage regimen of the FDC. In second approach i.e. in silico PK/PD modeling, dose response curve was 
constructed to estimate curve parameters (EC50 , γ, and Emax),  which were then used to develop PK/PD model for the FDC. In the third approach, 
MCS were employed to evaluate the impact of different dosage regimen against mild-to-severe infections.
Results: 
 Lastly, the recommendation of dose 
adjustments for patients with renal impairment was also presented. 
Based on all three approaches, the best antibacterial effect was obtained from the exposure of 20 x MICcomb, which when fractioned to 
twice-daily dosing showed a maximum reduction in bacterial densities for severe infections. Dose reduction was recommended for patients with 
several renal impairments. 
Keywords: PK/PD modeling, Monte-carlo simulations, Ceftriaxone, Sulbactam, Dose optimization 
Conclusion: FDC dosage regimen of 1.5g BD or 3g OD was recommended for mild to moderate infections; whereas 3g BD was required for severely 
infected patients. 
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
Extended-spectrum beta-lactamases (ESBLs) and metallo-β-
lactamases (MBL) represent major worldwide threat among 
resistant bacterial isolates, with its alarming prevalence in Europe 
and South-East Asian countries [1, 2]. Mono-therapy with a 
carbapenem is a currently available treatment against which 
increased in cases of resistance have been reported [3]. The limited 
therapeutic options coupled with dried pipeline of drug 
development guided us to look for alternatives. However, the 
scarcity of alternative options for monotherapy lead us to see 
beyond the effects of β-lactams and thus other non-antibiotic 
compounds like adjuvants have been studied for their activity along 
with antibiotics against ESBL-/MBL-producing isolates. 
INTRODUCTION 
The current fixed dose combination (FDC) of ceftriaxone/ 
sulbactam/Na2
After carefully selecting pharmacodynamics options for a FDC, the 
next step is dose optimization by identifying PK/PD relationships. 
The dosing regimens of antibiotics are based on MIC estimates (a 
surrogate PD marker for antibacterial response characterization) 
and the quantification of exposure (changes in the concentration of 
an individual component of FDC)-response (the reduction of 
bacterial count) relationship. The MIC estimates mainly explains 
antibiotic-infection relationship; whereas the exposure-response (E-
R) relationships identifies the PK/PD drivers which directly affect 
the therapeutic potential of anti-bacterial agents in clinical 
conditions. Maximum literature for these kinds of PK/PD studies is 
available for single antibacterial agents [7-9]; the effect of 
combination therapy on the PK and PD, and subsequently on PK/PD 
indices is very limited [10]. 
EDTA (2/1/0.074 w/w/w) was developed on same 
lines; where ceftriaxone is a base beta-lactam antibiotic and 
sulbactam is a beta-lactamase inhibitor; providing protection against 
ESBL and extending the antibacterial spectrum to cover 
Acinetobacter baumanni [4]. Additionally, the FDC has a non-antibiotic 
adjuvant ethylenediamine tetraacetate (EDTA), which further extends its 
anti-bacterial effect against MBLs. Mechanistically; ceftriaxone inhibits 
bacterial cell wall synthesis following attachment to penicillin binding 
proteins (PBPs) and exerts in vitro activity against a wide range of gram-
negative and gram-positive microorganisms [5]. Sulbactam prevents β-
lactamases induced inactivation of ceftriaxone through irreversible 
binding to the enzymes and prevents its further interaction with 
ceftriaxone. Therefore, sulbactam addition broadens the antibacterial 
spectrum of ceftriaxone. Also, third component i.e. EDTA [non-antibiotic 
adjuvant] synergise FDC action by chelating divalent ions produced by 
MBLs, reducing efflux transporter expression, inhibiting the conjugal 
transfer of resistant gene, eradicating bacterial biofilm, and inhibition of 
curli formation [6]. 
The objective of the present study was to predict the therapeutic 
efficacy of combination therapy and optimize the dosage regimen of 
the FDC formulation (fig. 1). Thus, in vitro studies were integrated 
with fractional inhibitory concentrations (FIC) approach to identify 
the optimum exposure and PK/PD driver of FDC under the specified 
conditions. The information was then utilized for dose optimization 
using in vitro method, PK/PD modeling and Monte-Carlo simulations 
(MCS). All three methods use same pieces of information as their 
input but vary in the specificity of output. The MCS, being least 
specific, have also employed population-PK parameters of 
ceftriaxone and sulbactam to carry out stochastic simulations, and 
for dose recommendation. Dose adjustment in case of renal 
impairment was also presented in the last section of the study. 
MATERIALS AND METHODS 
Compound, microorganism, and media 
The FDC of ceftriaxone/sulbactam/Na2EDTA (2/1/0.074) vials 
(Elores®) was obtained from Venus Pharma GmbH, Germany. 
Genetically characterized ESBL isolates (NCTC 13353; CTX-M-15) 
with reduced susceptibility to ceftriaxone were taken from isolate 
bacterial bank of Venus Medicine Research Centre, Baddi, India. 
Media Mueller-Hinton broth (Becton Dickinson, Sparks, MD) was 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                  Vol 8, Issue 7, 2016 
Taneja et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 7, 346-353 
347 
used to perform all in vitro studies involving MIC determination, 
bacterial kinetics, dose ranging, fractionation and response studies. 
Bacterial density, minimum inhibitory concentration, and 
fractional inhibitory concentration index determinations 
Bacterial density (colony forming units [CFU]), AST and MIC 
determinations were conducted according to Clinical Laboratory 
Standard Institute (CLSI) guidelines [11]. FIC index was determined 
using checkerboard method. 
 
Fig. 1: Schematics of the approach used in the study. In vitro 
studies were performed to study Exposure-Response (E-R) 
relationships and PK/PD driver identification. Using the 
information of in vitro studies, three approaches i.e. in vitro 
studies, PK/PD modeling, and Monte-Carlo simulations were 
employed for dose recommendations 
 
In vitro system 
One-compartment dilution system 
The in vitro modeling of FDC was done using a single-compartment 
chemostat infection system [12]. Briefly, the chemostat system 
assembly consisted of a 500 ml glass central reservoir chamber with 
ports for the addition and removal of media via silicone tubes 
connected to peristaltic pumps, injection of drug (antibiotic 
combination) solution, and removal of medium samples. Prior to 
each experiment, ESBL colonies were grown overnight to obtain a 
starting inoculum of 108
Hollow fiber system 
 CFU/ml in 500 ml central reservoir flask 
containing media. An aqueous solution of FDC was prepared in 
accordance with dilution advised by the manufacturer. The “in” and 
“out” flow rates from the central reservoir were adjusted as per the 
half-lives of active components. Samples from the central reservoir 
were collected at different time points from 0 to 24 h post-FDC 
addition. These samples were analyzed for individual component 
concentrations and CFU determination for bacterial densities. The 
bacteria growth control experiments were also performed using the 
same experimental set-up without adding any drug. Net PD effects of 
all doses of FDC were then reported after accounting the bacterial 
dynamics of the growth control experiment. Pre-and post-FDC 
exposure, MICs were determined for evaluating any changes in MICs 
due to FDC exposure or changed bacterial dynamics. 
The selected drug exposures were also evaluated in hollow fiber 
system [13]. Initial inocula of 108
Dose escalation, fractionation and dose response curve studies 
 CFU/ml was achieved by injecting 
10 ml of ESBL producing E. coli into extra-capillary space, which was 
separated from the central reservoir by semi-permeable hollow 
fibers. After 2 h of incubation in media, FDC was injected into the 
central reservoir. The drug can freely cross back and forth between 
the extra-capillary space and central reservoir so that ESBL E. coli 
were exposed to same drug concentration as those in the central 
compartment. Central compartment was connected to inlet and 
outlet reservoir through a pump whose flow rates were adjusted as 
per the half-lives of active components. Samples were collected from 
extra-capillary space for three days and were analyzed for drug 
concentration and bacterial densities. 
The in vitro chemostat model was used to perform dose escalation 
studies. The drug concentrations were varied from 1-200 folds MICs 
to determine the most efficacious exposure based on their PK/PD 
parameters. The best exposure from dose escalation study was then 
fractionated twice-a-day (BID) and thrice-a-day (TID) to determine a 
dosage regimen of antibiotic which can enhance bacterial killing at a 
lower concentration. The promising dosage regimen was then 
employed to construct dose-response curve (DRC). The dosage 
regimen at 80%, 50%, and 33% of original concentration, and the 
corresponding change in bacterial density in 24 h was measured. 
The DRC was plotted between the dose percentage and log reduction 
in bacterial density to calculate EC50 
Pharmacokinetic analysis 
(concentration required to 
produce half of the PD response). 
The concentrations-time profiles were fitted to one compartment 
model and PK parameters of ceftriaxone and sulbactam were 
calculated. The parameters included the area under the plasma 
concentration-time curve (AUC), highest concentration reached (the 
peak; Cmax), elimination rate constant (Ke), half-life (t1/2), the 
volume of distribution (VD
Pharmacokinetic/pharmacodynamic analysis 
), and clearance (CL). These parameters 
were calculated for all dose escalations and dose fractionation 
studies. The parameters obtained from concentration profile data 
were compared with reported PK parameters in the literature 
(Table 1). 
The FIC curves for ceftriaxone and sulbactam combinations were 
generated. Briefly, the concentrations of each antibiotic at every 
time-point were divided by their respective MIC contributions 
towards MICcomb to obtain FICceftriaxone and FICsulbactam values. These 
values were added (FICcomb) for each time points and plotted against 
time. The resultant FIC-time profile was fitted to one compartment 




In one compartment chemostat infection model, bacterial infection 
is dynamically exposed to an antibiotic formulation. During this time 
course, drug act on bacterial infection, and decrease the bacterial 
density. Since, the additional filter was not placed in the outlet of the 
in vitro chemostat system to check the bacterial elimination; the 
resultant bacterial loss was compensated in the model. A schematic 
illustration of PK/PD model is shown in fig. 2. 
 
 
Fig. 2: Schematics of the pharmacokinetics 
(PK)/pharmacodynamic (PD) model. The drug administered 
intravenously (IV) into one compartment in vitro system and 
follow first order elimination kinetics. Drug was in direct 
contact with bacterial infection (B), where it reduces the 
bacterial density either by inhibiting the growth rate (Kgrowth) 




Semi-mechanistic pharmacokinetic/pharmacodynamic modeling 
and validation 
a. Bacterial modeling 
The bacterial kinetics determination involves modeling of a single 
bacterial compartment (B) with first-order rate constants for 
bacterial multiplication (kgrowth) and bacterial death (kdeath) [14]. The 
equation 1 explains the observed exponential growth of bacteria 
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until it reaches a stationary bacterial level without the addition of 
antibiotics (control experiments); where B and Bmax are initial 
bacterial density and maximum bacterial density, and knet is (kgrowth-
kdeath




= knet ∗ (1 −
B
Bmax
) ∗ B … … … ….(1) 
The effect (E: bacterial load: PD endpoint) was evaluated at 8, 9.5, 12 
and 24 h. The relationship between the effect and the corresponding 
PK/PD indices was evaluated according to a sigmoidal Emax type 
function as described in equation 2 [14]: 
E = E0 −
PD max ∗Xhill
Xhill +EX 50 hill
… … … …. (2) 
Where, E is the PD endpoint i.e. bacterial density calculated as 
change in log10CFU/ml after 8, 9.5, 12 or 24 h of treatment, E0 is the 
baseline effect i.e. PD endpoint without antibiotic treatment; X is 
PK/PD index; PDmax is a maximum effect; EX50 is magnitude of X that 
is needed to achieve 50% of the PDmax;  Hill is the sigmoidicity factor, 
reflecting the steepness of the relationship. 
All data from the different dosing regimens was fitted to model 
mentioned above (equation 2). Curve fitting was performed in 
GraphPad Prism (version 4.01, GraphPad Software, San Diego, CA) 
using the non-linear regression analysis. The coefficients of 
determination (R2
c. Anti-bacterial-PK/PD modeling 
), sigmoidicity factor, and the visual inspection of 
observed versus predicted values graphs were used to select the best 
PK/PD index and the best-predicted endpoint of antibacterial effect. 
The basic assumption for the dependence of antibacterial effect is 
generally based on a non-linear relationship with concentration data 
of antibiotics. Higher the sigmoidicity factor, lesser is the 
predictability of PD effect with respect to PK/PD index. The 
concentration-effect relationships were incorporated in the bacterial 
model (equation 1) to predict the bacterial count from PK/PD model 
(equation 3). In the constructed model, the antibacterial effect of 
FDC of ceftriaxone/sulbactam is hypothesized as a combination of 
bacterial growth inhibition (kgrowth) and bacterial killing 
enhancement (kdeath
Model validation 
All data from the different drug exposure and dosage regimen was 
fitted to model mentioned above (equation 3) for the time period of 
8 and 24 h respectively using SCIENTIST (MicroMath, version 3.0, 
Saint Louis, Missouri, USA). The 95% confidence intervals were 
drawn for all the predicted values and compared with the observed 





= knet ∗ B − (
Emax∗Cγ
Cγ+EC50γ
) ∗ B … … … … (3) 
2
Monte-Carlo simulations 
Monte-Carlo simulations for 1000 adult subjects were performed to 
determine how likely the FDC dose of 0.75, 1.5, 3, 6, and 9 g would 
achieve 70% T>MIC
) between predicted and observed data values 
were determined and evaluated for the validation of the 
antibacterial-PK/PD model. 
comb at different values of MICcomb i.e. 1, 4, 8, 16, 
32, 64 µg/ml. The population-PK parameters (CL and Ke) were 
obtained from population-PK model of the FDC and were utilized in 
simulations. The concentration-profiles of once-a-day and twice-a-
day dosing regimens were generated using CL and Ke of each 
simulated subjects and %T>MICcomb was calculated for all simulated 
subjects for different exposures at all MIC values. The PTA (target 
PTA minimum 90%) was then defined as the percentage of 
simulated subjects showing %T>MICcomb of more than 70. 
Data analysis 
RESULTS AND DISCUSSION 
Dose optimization and its recommendation mainly depend on 
upon its pharmacological (including PK and PD) properties of a 
drug. The complexity increases with the addition of another active 
drug in the formulation, similar to the one presented in the study. 
The current formulation is a FDC of ceftriaxone and sulbactam in 
2:1 (w/w), mainly used for ESBL infections. The synergism of 
antibacterial effect of both drugs results in a reduction of MIC from 
256 to 8 µg/ml against bacterial strain NCTC 13353 (ESBL 
bacterial strain employed in this study). Also, FIC index of the FDC 
was less than 0.5 which confirms the pharmacodynamic synergism 
offered by FDC. 
MIC selection for in vitro studies using microbiological studies 
The ESBL producing E. coli isolates were used as a prototype of ESBL 
infections. Dose optimization of the FDC was performed using in 
vitro studies, PK/PD modeling and Monte-Carlo simulations. For in 
vitro studies, target MIC needs to be selected against which 
therapeutic effect of drug combination could be evaluated. The same 
information was also needed for other two approaches i.e. PK/PD 
modeling (for dose individualization based on bacterial density) and 
Monte-Carlo simulations (for dose recommendation based on MIC). 
Thus, the MIC selection was carried out using microbiological 
studies of ESBL isolates. 
A total of 515 strains of ESBL producing E. coli were collected from 
different Microbial Collection Centres across the country. Clinical 
breakpoints were determined using CLSI guidelines [11] and MIC 
distribution of bacterial isolates of E. coli were evaluated (fig. 3). As 
shown in fig. 3, more than 90% ESBL bacterial isolates exhibiting 
MIC of less or equal to 8 µg/ml were susceptible to FDC treatment. 
Also, MIC 8 µg/ml was at the borderline of clinical breakpoints of 
susceptible and intermediate bacterial strains, which means that the 
exposure-response relationship and resistance emergence (if any) 
against the FDC could be better identified at the given MIC. 
Therefore, MIC of 8 µg/ml was selected to carry out in vitro studies 
for dose optimization of FDC. 
Identification of optimum exposure against a given MIC 
In vitro studies for dose, optimization requires PK and PD inputs to 
evaluate the PK/PD of a given exposure of drug against an infection. 
For PK input, PK parameters reported in the literature [15-16] for 
ceftriaxone and sulbactam (table 1) were utilized. The PD target i.e. 
MIC of 8 µg/ml was selected using microbiological studies, as 
explained in above section. One compartment in vitro chemostat 
system with first order elimination was designed for dose 
optimization of FDC. The PD effect was defined as a logarithmic 
reduction in ESBL bacteria densities over 24 h period. 
The ESBL infection was treated with six different exposures (1-200 folds 
of MIC 8 µg/ml) of FDC for 24 h to find PK/PD driver that can predict the 
PD effect. Another objective was to find the lowest exposure that can 
give maximal PD effect against the infection. The drug concentration-
bacterial CFU-time profiles were obtained from in vitro chemostat 
model. Focusing on PK aspects, the PK parameters calculated in in vitro 
chemostat infection model for individual drugs were in concordance 
with reported literature values (table 1), suggesting successful 
reproduction of clinical conditions using in vitro system.  
Descriptive statistics were used for reporting all PK variables and 
summary tables were prepared using mean, standard deviation 
(SD), median, and range (whichever appropriate). Log transformed 
data was used wherever applicable. The statistical analysis was done 
using GraphPad Prism (version 4.01, GraphPad Software, San Diego, CA).  
In terms of PD effect, bacterial killing increase with an increase in drug 
exposure till the saturation is achieved (fig. 4a). After saturation (>20 
fold MIC for 9.5 h; >100 fold MIC for 24 h), there was no substantial 
increase in antibacterial effect. Dose of 100 x MIC was quite high, 
which can potentially affect therapeutic window of the drug 
combination. However, the dose of 20 x MIC (106.67 µg/ml of 
ceftriaxone and 53.33 µg/ml of sulbactam) was the minimum 
exposure for which maximum PD effect (~5 fold reduction) was 
observed after 9.5 h of drug administration; and moderate (~2 fold 
reduction) bacterial killing was seen post-24 h of drug treatment. 
Therefore, the exposure (20 x MIC) was selected for further dose 
optimization studies. 
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Fig. 3: MIC selection for in vitro studies using microbiological studies. (a) The plot of MIC values of various strains against the zone 
diameter for E. coli and segregated based on the MIC breakpoints of 8 and 32 mg/l; (b) The distribution of the bacterial isolates of E. coli 
based on their MICs. R: Resistant, I: Intermediate, S: susceptible 
 
Table 1: Pharmacokinetic parameters of ceftriaxone and sulbactam employed in the study [15-16] and their comparison with the values 
estimated from in vitro one compartment dilution system 
Parameters As reported in literature Estimated from in vitro system 
Ceftriaxone Sulbactam Ceftriaxone Sulbactam 
Clearance (L/h) 0.88 11.90 1.13 11.10 
Volume of distribution (L) 10.1 22.82 12.3 20.87 
Half life (h) 5.9 0.97 7.42 1.5 
 
 
Fig. 4: Selection of dosage regimen using dose escalation (a) and dose fractionation (b). As shown above in dose escalation (a), exposure of 
20x MIC was optimum and thus selected for further dose fractionation (b) in which the dose was divided into twice-a-day (BD) and thrice-
a-day (TD) regimen and corresponding change in bacterial density (Δ log10
 
 CFU) was observed 
Identification of PK/PD driver for therapeutic outcome 
Further dose optimization of FDC requires an understanding of 
PK/PD driver responsible for the therapeutic potential of the FDC. 
For instance, if the FDC's PD effect is exposure (AUC)-dependent, it 
is recommended to increase both dose (increase Cmax) and dose 
frequency (increase %T>MIC) to increase the anti-bacterial 
response of FDC. Thus, identification of PK/PD driver of the FDC was 
then carried out using sigmoidal-Emax model [14]. Since, the present 
formulation is a combination of drugs, fractional inhibitory 
concentrations (FIC) approach was used for PK/PD analysis in order 
to combine the contribution of both drugs as per their concentration 
and MIC contribution in the FDC [10]. Briefly, FIC-time profiles were 
generated from concentration-time profile of both drugs for all 
doses as described above (See ‘PK/PD analyses' in 'Materials and 
Method' section). The PK/PD indices i.e. AUCcomb, %T>MICcomb
The objective was to find the PK/PD index that can predict the 
antibacterial effect of the FDC as a single unit. From FIC-t profiles, 
AUC
 and 
%T>FIC were calculated from the FIC-time curves. All PK/PD indices 
were plotted against the logarithmic reduction in bacterial densities 
of E. coli ESBL strain for 8, 9.5, 12 and 24 h. The time periods of 8, 12 
and 24 h were chosen considering TID, BD and OD regimen of the 
FDC. The time point of 9.5 h was included because the second 
inoculum was added at this time point which might affect the net 
reduction in bacterial density. The PD effect was found to be better 
correlated with 9.5 h and 24 h time point as compared to 8 and 12 h, 
thus shown here in fig. 5. 
comb, %T>MICcomb, and %T>FIC were calculated and plotted 
against bacterial killing post 9.5 h and 24 h drug exposure (fig. 5). 
The data was fitted with a sigmoidal-Emax type function (see 
'materials and methods', equation 2) and selection of best PK/PD 
driver was done based on coefficient of correlation, and sigmoidal 
factor. Sigmoidal factor is the steepness of the sigmoidal curve and 
represents the predictability of the model. Higher the steepness, 
lesser is the predictability of the model. It must be noted that the 
initial concentration or Cmax-comb is pre-decided when the drug was 
injected in in vitro system. Higher coefficients of correlation of 
logCmax-comb
Focusing on results, higher correlation coefficient were obtained 
after 24 h drug treatment as compared to ones after 9.5 h [compare 
correlation coefficients after 9.5 h (fig. 5a) vs 24 h (fig. 5b), i.e. 0.91 
 vs. log ΔCFUs were obvious and, thus not considered to 
identify the PK/PD driver of the current FDC. 
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vs 0.98 for log AUCcomb; and 0.87 vs 0.98 of %T>MICcomb]. The %T>FIC 
was poorly correlated with bacterial reduction. Focusing on 24 h drug 
exposure, the R2 is highest for %T>MICcomb i.e. 0.9880 with high 
predictability (γ = 3.38). The good R2 of 0.9873 was also obtained from 
the plot of logAUCcomb vs log ΔCFU, but steepness was quite high, which 
restricts the predictability of the model (γ =14.25; average 
predictability) (fig. 5b). The high value of sigmoidicity factor suggests all-
or-none function of the system and thus decreases the predictability of 
model. Therefore, % T>MICcomb was considered the best PK/PD driver 
followed by AUCcomb
 
, to predict the PD effect of FDC in the study. 
 
Fig. 5: Selection of PK/PD drivers of the FDC using fractional inhibitory concentration (FIC) approach. Three PK/PD drivers i.e. Log10AUCcomb, 
%T>MICcomb, and %T>FIC were plotted against corresponding pharmacodynamic effect after 9.5 h (a) and 24 h (b) [measured as Δ log10 CFU]. The 
sigmoidal Emax
 
 model was employed to find the best fit for the observed data to identify PK/PD driver of the FDC 
After selection of PK/PD driver (i.e. %T>MIC), the next objective was to 
identify a desired value of %T>MIC that one should target to assure good 
therapeutic effect of the FDC. Thus, plot of %T>MIC vs. Δ log10
The identification of PK/PD driver of FDC and its desired value was 
further used for dose optimization and recommendation. Three 
approaches were used i.e. in vitro approach, PK/PD modeling and 
Monte-Carlo simulations. All three approaches use same piece of 
information and give useful information for dose optimization and 
vary from each other in terms of specificity of information. The first 
approach (in vitro approach) mainly tells about the therapeutic 
potential of a certain drug under a specific MIC. The PK/PD model is 
generally employed for dose individualization; whereas, Monte-
Carlo simulations broadly recommends dose regimen based on MIC 
of the target infection. All three approaches were utilized and 
explained below. 
CFU was 
evaluated to estimate desired %T>MIC value (fig. 5 b-ii). It was clearly 
observed that PD effect of the FDC become saturated after 70 %T>MIC, 
prompting us to select 70 as a target value of PK/PD i.e. %T>MIC for 
dose optimization. In other words, one can assure good therapeutic 
effect of the FDC, if the drug concentration in body remains above MIC 
for more than 70% of the time of drug exposure. 
Dose optimization using in vitro system 
a. One-compartment dilution system 
The time-dependence of FDC to exhibit its PD effect, prompted us to 
fractionate the dose, with an objective to increase the duration of 
exposure (above MIC) and decrease the overall concentration (to 
reduce side effects). As explained above, the dose exposure of  
106.67/53.33 µg/ml (ceftriaxone/sulbactam) was selected for dose 
fractionation. Considering the patient compliance, antibiotic half-life, 
and MIC of drug against E. coli ESBL strains, dose was fractionated to 
mimic a dosage regimen of once-a-day (OD), twice-a-day (BID), and 
thrice-a-day (TID). Similar to dose escalation study, the in vitro 
dilution system was used for these dosage regimens and results are 
shown in fig. 4b. The antibacterial effect of the FDC was increased 
from once-a day dosing to twice-a-day dosage regimen in 24 h time 
period (~2 fold to ~5 fold reduction in bacterial density). Further 
fractionation of dose (i.e. TID) decreases the drug concentration 
below MIC for longer time period and thus reduces the time of 
exposure during which the drug concentration remains above the 
MIC (only 0.2 fold reductions in bacterial density). The selected 
dosage regimen roughly corresponds to 3.0 g FDC of ceftriaxone 
(2 g) and sulbactam (1 g), after correcting for protein binding of 
80% and 38%; and volume of distribution of 10.1 L and 18-25 L of 
both components i.e. ceftriaxone and sulbactam respectively (Table 
1). The MIC values remained same during 24 h drug-bacterial 
incubation period for all drug exposures (data not shown), thus 
ruling out the possibility of antimicrobial resistance development in 
E. coli ESBL isolates during in vitro studies. 
b. Hollow fiber system 
In vitro dilution system is considered good for evaluating exposure-
response relationship of a drug. However, it is sub-optimal in 
mimicking clinical conditions where bacterial suspension is 
concentrated in a small volume with no bacterial loss. Therefore, 
hollow fiber system was employed to confirm the results of 3 g BD 
dose of FDC, obtained from in vitro dilution system for. As expected, 
similar results were obtained from hollow fiber system, where the 
bacterial killing of 3 log reductions was observed for 3 g twice-a-day 
regimen. The relatively lower bacterial reduction in case of hollow 
fiber system as compared to in vitro dilution system was a result of 
more rigorous and closer-to-reality set-up of hollow fiber system; 
where the bacterial infection was kept in extracellular matrix 
secluded from the central compartment through a semi-permeable 
membrane [13]. The hollow fiber set-up elevates the severity of 
bacterial infection, manifested as lower CFU reduction, by 
preventing bacterial loss and providing a favourable condition for 
resistance development. The results of both in vitro systems have 
shown similar antibacterial efficacy for 3.0 g BD dosage regimens in 
adults. To summarize, a dose of 3 g BD is to be fractionated into 
twice-a-day dosage regimen to maintain the same therapeutic 
efficacy while keeping the possibilities of adverse events low. 
Dose optimization using PK/PD modeling 
a. PK/PD model development 
The PK/PD model was developed using equation 3 of sub-section 
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section 'antibacterial-PK/PD modeling' under 'Materials and 
Method' section, which was a differential equation with one 
independent (T) and two dependent variables (B and C). The remaining 
variables were Knet, Emax, EC50 and γ. The bacterial net growth (Knet) was 
determined from growth kinetics of bacteria without adding drug. For 
the determination of Emax, EC50 and γ, dose-response curves (DRC) were 
constructed and analyzed using in vitro dilution system. 
The dose-response relationship is an important aspect of any drug 
as it directly relates the dose of the drug with its pharmacological 
action. Depending upon the therapeutic action needed, the dose can 
be adjusted to enhance therapeutic effects using the dose-response 
relationship. ESBL infections were exposed to 33%, 50%, 80% and 
100% of a dosage regimen in in vitro chemostat system and the 
corresponding logarithmic change in bacterial densities of-2.3, 1.0, 
3.8 and 4.7 were observed respectively. The DRC was plotted (fig. 6) 
and the data was fitted with sigmoidal function; and EC50 of 49 % 
(defined as a percentage of dose required to attain the 50 percent of 
PD effect), γ of 5.06 (steepness of DRC curve) and E max
 
Fig. 6: Dose-response curve (DRC) of the FDC was plotted 
between different fractions [0, 33, 50, 80 and 100%] of FDC 3.0 
g BD and the corresponding changes in bacterial densities to 
calculate EC
 of 5.7 
(maximum therapeutic effect displayed by FDC) was calculated. All 
these parameters were employed to develop a semi-mechanistic 
antibacterial bacterial-PK/PD model. 
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 and gamma (γ) value. The net therapeutic effect 
of all dose fractions was increased by 2 units to convert all 
negatives CFU values [corresponding to lower drug 
concentrations] into positive values 
 
The final PK/PD equation was validated to check its suitability in 
dose recommendation using SCIENTIST. The experimental data of 
dose escalation studies was fitted using equation 3. The goodness of 
fit and 95% confidence interval of simulated data were evaluated for 
first 8 h (before the addition of the second inoculum). Simulations 
after 8 h of drug exposure were not shown in the case of dose-
escalation study in order to focus mainly on initial exposure of drug, 
where most of the bacterial killing occurred. The semi-mechanistic-
PK/PD model has moderately predicted the drug exposure. For 
instance, R2
In the case of dose fractionation, dose frequency was the main 
factor; thus model predictions were extended to 24 h. The observed 
values of experiments and predicted values of the model were 
plotted for all three dosage regimens i.e. once-a-day, twice-a-day and 
thrice-a-day (fig. 7-II). The addition of the second inoculum at 9.5 h 
had raised the CFU counts, as shown by a downward peak in all 
three cases. Also, the model had weaker predictability at lower 
concentrations of the drug, as observed in PD prediction during 20–
24 h for all three dose frequencies of FDC. Therefore, the weaker 
correlation was observed in all three cases as compared to dose 
escalation studies. The correlation coefficient was increased from 
0.4506 of once-a-day dosing to 0.6361 of twice-a-dosing of the FDC 
of antibiotics. Further increase in dose fractionation drastically 
reduced the correlation coefficient to 0.2703, which suggests the 
model weakness in the prediction of lower drug concentrations. 
However, the model was appropriate for the twice-a-day dose 
frequency, which was also the best dosage regimen for FDC 
according to in vitro results. The same conclusions were derived 
from 95% confidence interval of simulated data. Most of the data of 
twice-a-day dosing were in the upper and lower limits of the 
confidence interval, followed by once-a-day dosing (fig. 7-II). As 
expected in the case of thrice-a-day dose frequency, predicted values 
were poorly correlated with the experimental values. 
 values for the fitted values of dose exposures of 10x, 20x 
and 100x MIC were 0.7508, 0.7154 and 0.8914 respectively (fig. 7-I) 
suggesting good predictability of model under given exposures. 
Additionally, most of the experimental data points were under 95% 
confidence interval of simulated data, which further supports the 
validity of PK/PD model. 
Dose optimization using monte-carlo simulations 
The in vitro studies were done using the fixed values of primary PK 
parameters and MIC; which did not account for variability in the 
clinical population. Therefore, Monte-Carlo simulations were 
performed in order to account for the randomness in human PKs 
and MICs. The probability of target attainment (PTA) was defined 
using in vitro results, which is a percentage of simulated subjects 
showing %T>MICcomb
 
 of more than 70 (fig. 8). The objective was to 
identify the antibiotic exposure that can give maximum bacterial 
killing with minimal side effects. 
 
Fig. 7: Validation of PK/PD model for the data of dose-escalation (I) and dose fractionation (II) studies using SCIENTIST. Weaker predictions 
were observed at a lower concentration of FDC. Dotted lines represent 95% confidence interval of the predicted values, whereas the solid 
lines represent prediction by the final PK/PD model. Solid squares represent the observed values obtained from in vitro studies 
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Monte-Carlo simulations of 1000 concentration-time profiles were 
performed using population PK parameters estimated from both 
populations (healthy and infected) combined. The population PK 
parameters utilized in simulations were CL of 0.75±0.2 L/h and 
16.52±4.63 L/h for ceftriaxone and sulbactam respectively [17]. The 
Ke was set to 0.09 and 0.51 for ceftriaxone and sulbactam 
respectively. The FDC in a dose range of 0.75 to 9 g as OD and BD 
regimen were used to calculate PTA over a range of MICcomb
In summary, a high PTA (≥90%) for a target 70%T>MIC with MIC ≤8 
µg/ml was observed with 1.5 g BD dose; and with same total exposure in 
OD dose (3 g), ~80% PTA was attained. The dosage regimen of 3g BD 
showing PTA of 100% indicates the improvement in response if 
required, in cases of severe infections. This claim was further supported 
from the clinical data of cUTI patients, where >90% cure was achieved 
with 3 g BD FDC dose [18]. The results were also in conformance with 
the dose optimization study of the FDC in paediatrics [19]. 
 (1-64 
µg/ml) (fig. 7). The FDC was noted to be very effective with PTA of 
~100% at dose strength ≥ 1.5 g OD and ≥0.75g BD for the strains 
corresponding to MIC of 1 and 4 µg/ml. For MIC 8 µg/ml, doses less 
than 3g were not effective. Even 3 g OD achieved PTA~80%, which 
can be improved to 95% when the same exposure was divided into 
two doses (1.5 g BD). Further increasing the dose to 3 g BD 
maximized the PTA to 100%. For MIC 16 µg/ml, OD regimen was 
ineffective as the maximum PTA achieved at highest 9 g OD dose was 
only 35%. The FDC was ineffective at all drug exposures (PTA~0-
5%) for the MIC of 32 and 64 µg/ml. 
Recently, Sharma et al. have reported cost effectiveness of the FDC at 
the same dosage regimen of 3 g BD over meropenem treatment [20].
 
 
Fig. 8: Monte-Carlo simulations of 1000 subjects were performed and PTA (70 %T>MIC) was calculated for 0.75-9.0 g once-a-day (a) and 
twice-a-day (b) dosage regimen of FDC against MIC of 1-64 µg/ml 
 
Dose optimization for renal impairment 
Subjects with renal impairment have reduced renal clearance as per 
the severity of the disease. Reduction in renal clearance of drug 
would increase the net drug exposure and thus necessitate dose 
reduction to avoid adverse side effects without compromising 
therapeutic effect. Ceftriaxone undergoes 50-60% renal clearance; 
whereas sulbactam has the renal clearance of 70-80% [15, 16]. Dose 
adjustments were done based on achieving PK/PD driver i.e. 70% 
T>MIC using the PK parameters of mild, moderate, severe and 
hemodialysed patients (fig. 9). The assumption was made that body 
would not initiate any compensatory mechanism in case of reduced 
renal clearance. It was observed that only 4-7% dose reduction in 
both OD and BD regimen was required for mild renal impairment. 
However, in principle, this minor dose reduction can easily be 
compensated by the body. Additionally, ceftriaxone was mainly 
responsible for the therapeutic action of the FDC and had another 
major route of elimination (biliary excretion).  
Therefore, dose reduction was not required for mild renal impairment. 
However, the same conclusion was not valid for patients with moderate 
to severe renal impairment. For moderate-to-severe infection, 37-38% 
dose reduction in OD and BD regimen was recommended. In case of 
anephric patients, a significant reduction in renal clearance occurs and 
thus dose should be reduced by 40-50% for the same therapeutic effect. 
To summarize, there was no need to adjust the dose of the FDC in 
patients with mild renal diseases; whereas dose reduction would be 
required for severe renal impairment cases. 
 
 
Fig. 9: Dose adjustment in renal impairment for once-a-day (a) and twice-a-day (b) regimen 
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CONCLUSION 
Dose optimization of fixed dose combination of ceftriaxone/ 
sulbactam/Na2EDTA (2/1/0.074) was performed using three 
approaches i.e. in vitro systems, semi-mechanistic PK/PD modeling 
and Monte-Carlo simulations. In the first approach (in vitro system), 
the best antibacterial effect was obtained from the exposure of 20x 
MICcomb which when fractioned to twice-daily dosing showed a 
maximum reduction in bacterial densities. The second approach 
(semi-mechanistic PK/PD model incorporating bacterial kinetics and 
drug’s PK/PD relationship) have showed good predictability at 
therapeutic exposures. Using the third approach (stochastic 
simulations with PTA of 70%T>MIC), further dose recommendations 
were made, wherein, 1.5 g BD or 3 g OD can combat pathogens up to 
MIC of 8 µg/ml; while for combating pathogens with MIC 16-32 µg/ml, 
3 g BD would provide benefit. Thus, the study corroborates the validity 
of antibacterial effect of FDC ceftriaxone/sulbactam/Na2
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